secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001559053-23-000002
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports Q4 net income $6.3M, full year net loss $116.9M; provides 2023 guidance
--------------------------------------------------------------------------------

- Q4 2022 revenue $49.9M (incl. $40M Novo Nordisk milestone); full year revenue $53.9M vs $200.6M in 2021.
- Cash, cash equivalents and restricted cash $712.6M at Dec 31, 2022; no debt.
- 2023 guidance: net cash used in operating/investing $213-229M; year-end cash ~$512M.
- PRX012 Phase 1 topline data expected year-end 2023; PRX005 Phase 1 MAD topline also year-end 2023.
- Birtamimab Phase 3 AFFIRM-AL topline data expected 2024; prasinezumab Phase 2b topline 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000002/0001559053-23-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905323000002/prta-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001559053-23-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer